Genetically engineered virus plus immunotherapy takes on deadly brain tumors
NCT ID NCT05084430
First seen Jan 28, 2026 · Last updated Jun 19, 2026 · Updated 13 times
Summary
This early-phase trial tests a combination of two treatments for people with glioblastoma and other aggressive brain cancers. One treatment is a genetically modified herpes virus (M032) that is injected into the tumor to stimulate the immune system. The other is pembrolizumab (Keytruda), an immunotherapy drug given by IV. The study aims to see if the combination is safe and whether it can improve survival. About 28 participants with recurrent or newly diagnosed disease will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab and M032 (a genetically engineered herpes simplex virus that produces IL-12)
What this could lead to
If successful, this could point toward a new treatment option for aggressive brain cancers like glioblastoma, potentially extending survival.
What could go wrong
This is an early-phase trial with only 28 participants, so results may not apply to all patients. The virus and immunotherapy combination could cause serious side effects, including brain inflammation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.